Seres Therapeutics, Inc. - Special Call Transcript
Good day, ladies and gentlemen, and welcome to the Seres Therapeutics Phase III Update Call.
(Operator Instructions) As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Mr. Carlo Tanzi, Head of Investor Relations.
Thank you, and good morning. Our press release and accompanying slide presentation, with the positive results of the company's SER-109 Phase III study and a business update, became available earlier this morning and can be found on the Investors and Media section of the company's website.
I'd like to remind you that we will be making forward-looking statements relating to the SER-109 regulatory approval time line, the market and commercial opportunity for SER-109, the potential for SER-109 to transform the treatment of recurrent CDI, the need for additional safety data to support regulatory approval, the validation of Seres' platform and its impact on a broad range of diseases. Actual results
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
